G13.2
Systemic atrophy primarily affecting the central nervous system in myxedema
Clinical Classification Guidelines
Code First
- underlying disease, such as:
- hypothyroidism (E03.-)
- myxedematous congenital iodine deficiency (E00.1)
Medical Intelligence & Overview
Systemic atrophy primarily affecting the central nervous system in myxedema is a rare but serious condition characterized by the progressive degeneration of nerve cells and tissues within the brain and spinal cord. This condition is linked with myxedema, a severe form of hypothyroidism where the body's tissues become swollen and sluggish due to thyroid hormone deficiency. Recognizing the signs and understanding the underlying causes is essential for monitoring and managing the condition effectively.
Causes & Symptoms
Clinical Causes: Prolonged hypothyroidism leading to metabolic disturbances in neural tissues Autoimmune disorders attacking the thyroid gland and affecting nervous tissue Genetic predispositions that influence nerve tissue degeneration Nutritional deficiencies, particularly iodine or selenium, impacting thyroid and nervous health Environmental toxins contributing to neural tissue damage Chronic inflammatory conditions affecting the nervous system
Key Symptoms: Progressive weakness and fatigue Cognitive decline, such as memory problems and confusion Muscle wasting and involuntary movements Loss of coordination and balance issues Sensory disturbances like numbness or tingling Speech difficulties and impaired swallowing Changes in mental state, including depression or apathy Physical signs of myxedema such as swelling of the face and extremities
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a comprehensive clinical examination, detailed medical history, and specialized tests. These include blood tests to assess thyroid hormone levels and markers for autoimmune activity. Neuroimaging studies like MRI or CT scans can visualize structural changes within the brain and spinal cord, revealing areas of atrophy. Electrophysiological studies may also be used to evaluate nerve function. Because symptoms overlap with other neurological conditions, a multidisciplinary approach helps confirm the diagnosis.
Treatment Protocols: Treatment primarily focuses on managing the underlying hypothyroidism with thyroid hormone replacement therapy. Addressing nutritional deficiencies and controlling autoimmune components, if present, are also vital. Supportive therapies such as physical and occupational therapy can help maintain mobility and function. Regular monitoring and adjusting therapy based on patient response are essential for optimizing outcomes. Interdisciplinary management involving neurologists, endocrinologists, and other specialists enhances the quality of care.
Clinical Advice & FAQs
Billing Guidance
Is G13.2 a billable ICD-10 code?
Yes, G13.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G13.2?
Clinical documentation must specify the nature of Systemic atrophy primarily affecting the central nervous system in myxedema and any associated comorbidities for accurate reporting.
Cite this Clinical Reference